Paper linking COVID-19 vaccines to myocarditis is temporarily removed without explanation

A paper claiming that myocarditis cases spiked after teenagers began receiving COVID-19 vaccines has earned a “temporary removal” — without any explanation from the publisher.

[Please see an update on this post.]

The article, “A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products,” was published in Current Problems in Cardiology, an Elsevier journal, on October 1.

It was co-authored by Jessica Rose and Peter McCullough, whose affiliations are listed as the Public Health Policy Initiative at the Institute of Pure and Applied Knowledge — a group that has been critical of vaccines and of the response to COVID-19 and has funded one study that was retracted earlier this year — and Texas A&M’s Baylor Dallas campus. [See update at the end of the post.]

Continue reading Paper linking COVID-19 vaccines to myocarditis is temporarily removed without explanation

Author defends paper claiming COVID-19 vaccines kill five times more people over 65 than they save

Ronald Kostoff

The corresponding author of a new paper in an Elsevier journal that claims “there are five times the number of deaths attributable to each inoculation vs those attributable to COVID-19 in the most vulnerable 65+ demographic” says he “fully expected” the criticisms — and that the “real-world situation is far worse than our best-case scenario.”

Ronald Kostoff and colleagues published “Why are we vaccinating children against COVID-19?” in Toxicology Reports in mid-September. In the paper, they colleagues conclude:

Continue reading Author defends paper claiming COVID-19 vaccines kill five times more people over 65 than they save

Elsevier corrects a retraction notice following questions from Retraction Watch

An Elsevier journal has corrected a retraction notice after we asked questions about what exactly it was saying — but not before the journal’s editor tried to defend what turned out to be a mistaken passage.

The article, “Measurement of performance parameters and improvement in optimized solution of WEDM on a novel titanium hybrid composite,” was published online in Measurement in December 2020. The retraction notice, which appeared online on September 17 of this year, read:

Continue reading Elsevier corrects a retraction notice following questions from Retraction Watch

Authors admit they “published the paper without completely studying their work.”

As readers of this blog know, we’re fond of highlighting euphemisms, particularly for plagiarism: “inadvertently copied text,” “a significant originality issue” and and “inclusion of significant passages of unattributed material from other authors” come to mind.

But here’s a euphemism for “bullshit” that’s new to us.

Continue reading Authors admit they “published the paper without completely studying their work.”

Vice-chancellor of university in Pakistan loses paper for plagiarizing from a thesis

Muhammad Suleman Tahir

Sometimes, imitation is not the sincerest form of flattery.

Ask Farukh Iqbal. Earlier this year, Iqbal, of the Department of Chemical and Environmental Engineering at RMIT University, in Melbourne, Australia, was alerted to a recent paper in the journal Fuel that cited a 2020 article he’d written with some colleagues. 

Iqbal read the paper and realized with dismay that not only was his work — which included parts of his thesis — cited, it was plagiarized:

Continue reading Vice-chancellor of university in Pakistan loses paper for plagiarizing from a thesis

‘Tortured phrases’, lost in translation: Sleuths find even more problems at journal that just flagged 400 papers

Guillaume Cabanac

What do subterranean insect provinces and motion to clamor have to do with microprocessors and microsystems?

That’s an excellent question. Read on, dear reader.

Continue reading ‘Tortured phrases’, lost in translation: Sleuths find even more problems at journal that just flagged 400 papers

Elsevier retracts entire book that plagiarized heavily from Wikipedia

The periodic table is, as a recent book notes, a guide to nature’s building blocks. But the building blocks of said book appear to have been passages from Wikipedia.

The book, The Periodic Table: Nature’s Building Blocks: An Introduction to the Naturally Occurring Elements, Their Origins and Their Uses, was published by Elsevier last year. But in December, Tom Rauchfuss, of the University of Illinois Urbana-Champaign, “tipped off by an Finnish editor on Wikipedia,” alerted the authors and Elsevier about the apparent plagiarism from the online encyclopedia.

On January 6, an Elsevier representative told Rauchfuss:

Continue reading Elsevier retracts entire book that plagiarized heavily from Wikipedia

How hijacked journals keep fooling one of the world’s leading databases

Anna Abalkina

It keeps happening. 

There was the case of Talent Development and Excellence, which cloned an existing journal and managed to index hundreds of articles in Scopus, one of the world’s leading databases for scholarly literature. The Transylvanian Review did the same thing, and so did Test Engineering and Management.

These journals — which can make millions of dollars for their illegitimate publishers — exploit vulnerabilities in Scopus, owned by Elsevier, by making themselves look close enough to real journals, often exploiting the real ISSN and other metadata of those titles. That, in turn, entices potentially unknowing authors whose careers may depend on publishing in journals in major indexes.

Now into the mix comes Annals of the Romanian Society for Cell Biology. This time, the tip-off, discovered by Russian scholar Dmitry Dubrovsky, was almost unbelievable: an article about the Great Patriotic War — the Soviet resistance to Germany’s 1941 invasion — in a journal specializing in biochemistry, genetics, and molecular biology.  

Continue reading How hijacked journals keep fooling one of the world’s leading databases

Antiviral: ‘TikTok Doc’ loses paper on faculty development over concerns about harassment suit

Jason Campbell

The now-infamous “TikTok Doc” who was embroiled in a recently settled sexual harassment suit has lost a 2020 paper on, wait for it, faculty development after his co-authors decided that the collaboration risked “reputational damage” to themselves and dismissal of the work. 

Jason Campbell was an anesthesiology resident at Oregon Health & Science University, in Portland, when he became a social media darling. Clips of him dancing in the hospital during the Covid-19 pandemic went viral on TikTok — before Campell was accused of sexually harassing a social worker at the Portland VA hospital, where the anesthesiologist sometimes worked. (Campbell left the institution and reportedly now lives and works in Florida.)

According to The Oregonian, the suit against Cambell and OHSU alleges that: 

Continue reading Antiviral: ‘TikTok Doc’ loses paper on faculty development over concerns about harassment suit

Clinical trial paper that made anemia drug look safer than it is will be retracted

via Kidney International Reports

A study that a pharmaceutical company admitted last month included manipulated data will be retracted, Retraction Watch has learned.

The paper, “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis,” was published in Kidney International Reports in December 2020. The study analyzed data from a clinical trial for roxadustat, a drug intended to help anemic patients make more red blood cells. The medicine was tested in more than 1,500 patients with kidney failure that had been on dialysis for less than four months.

The paper compared roxadustat to a standard treatment, epoetin alfa. Epoetin alfa is not given to anemic patients who have kidney disease and are not dependent on dialysis, according to reporting in April by FiercePharma, because it can increase the risk of a cardiovascular event, including heart attacks.

In the study, roxadustat was as effective as epoetin alfa for these patients, but carried a 30 percent lower risk for death, heart attacks or strokes.

Then, on April 6th, Fibrogen announced, according to FiercePharma, that researchers had

Continue reading Clinical trial paper that made anemia drug look safer than it is will be retracted